Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
US11718652B2 · kind B2 · utility
0Cited by
10References
35Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 21, 2021 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | Apr 1, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.